

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/600,816	06/20/2003	Gena S. Whitney	D0251 NP	5150
23914 LOUIS J. WILI	7590 03/29/200 LE	EXAMINER		
BRISTOL-MYERS SQUIBB COMPANY PATENT DEPARTMENT P O BOX 4000			LI, RUIXIANG	
			ART UNIT	PAPER NUMBER
PRINCETON, NJ 08543-4000			1646	
SHORTENED STATUTOR	Y PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE	
3 MONTHS		03/29/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

	Application No.	Applicant(s)		
	10/600,816	WHITNEY ET AL.		
Office Action Summary	Examiner	Art Unit		
	Ruixiang Li	1646		
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet with the c	orrespondence address		
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING D. - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period of Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tin will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).		
Status				
1) ⊠ Responsive to communication(s) filed on 30 Ja 2a) ⊠ This action is FINAL. 2b) □ This 3) □ Since this application is in condition for allowal closed in accordance with the practice under E	action is non-final. nce except for formal matters, pro			
Disposition of Claims		• .		
4) ☐ Claim(s) 35-44 is/are pending in the application 4a) Of the above claim(s) 37 and 39-44 is/are v 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 35, 36, and 38 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/o	withdrawn from consideration.			
Application Papers				
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) accomplicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Examine	epted or b) objected to by the I drawing(s) be held in abeyance. See tion is required if the drawing(s) is ob	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).		
Priority under 35 U.S.C. § 119				
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 				
Attachment(s) 1) \(\sum \) Notice of References Cited (PTO-892) 2) \(\sum \) Notice of Draftsperson's Patent Drawing Review (PTO-948)	4) ☐ Interview Summary Paper No(s)/Mail Da			
2) ☐ Notice of Draitsperson's Patent Drawing Review (P10-948) 3) ☑ Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 1130/2003	5) Notice of Informal P			

Application/Control Number: 10/600,816

Art Unit: 1646

DETAILED ACTION

Page 2

Status of Application, Amendments, and/or Claims

The amendment filed on 01/30/2007 has been entered. Claims 35 and 36 are amended.

Claims 35-44 are pending. Claims 35, 36, and 38 are under consideration.

Withdrawn Objections and/or Rejections

The objection to title is withdrawn in view of amended title.

The rejection of claims 35, 36, and 38 under 35 U.S.C. 112, first paragraph for scope of

enablement is withdrawn in view of amended claims.

The rejection of claims 35, 36, and 38 under 35 U.S.C. 112, second paragraph is

withdrawn in view of amended claims.

Information Disclosure Statement

The information disclosure statement filed on 1/30/2007 has been considered by the

examiner and an initialed copy has been attached to this office action

Claim Rejections Under 35 U. S. C. § 102 (e)

(i). The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that

form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

Art Unit: 1646

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

(ii). The rejection of claims 35, 36, and 38 under 35 U.S.C. 102(e) as being anticipated by Veiby et al. (U.S. Pub. No. US2003/0068636 A1, April 10, 2003; 102(e) date: 06/21/2001) is maintained.

Applicants argue that Veiby et al. fails to teach all of the elements of claim 35 on account of it not disclosing a "polypeptide consisting of the sequence of amino acids 2 to 357 of SEQ ID NO: 3.

Applicants' argument has been fully considered, but is not deemed to be persuasive because claim 35, a) recites a step of determining the expression level of RNA encoding a polypeptide of the sequence of amino acids 2 to 357 of SEQ ID NO: 3 in a normal tissue sample and in a test tissue sample by measuring RNA of said polypeptide. Veiby et al. teach a nucleic acid marker (SEQ ID NO: 59) for breast cancer (see Table 2) that is 100% identical to the nucleic acid sequence of SEQ ID NO: 2 of the present invention (see sequence alignment attached to the previous office action), whereas the complementary sequence of such a nucleic acid sequence can be used to determine the expression level of RNA encoding a polypeptide consisting of 2 to 357 of SEQ ID NO: 3, as recited in claim 36, a).

Application/Control Number: 10/600,816

Art Unit: 1646

Conclusion

No claims are allowed.

THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the

extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE

MONTHS from the mailing date of this action. In the event a first reply is filed within

TWO MONTHS of the mailing date of this final action and the advisory action is not

mailed until after the end of the THREE-MONTH shortened statutory period, then the

shortened statutory period will expire on the date the advisory action is mailed, and any

extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of

the advisory action. In no event, however, will the statutory period for reply expire later

than SIX MONTHS from the mailing date of this final action.

Advisory Information

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Ruixiang Li whose telephone number is (571) 272-0875.

The examiner can normally be reached on Monday through Friday from 8:30 am to 5:00

pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Gary Nickol, can be reached on (571) 272-0835. The fax number for the

organization where this application or proceeding is assigned is (571) 273-8300.

Page 4

Application/Control Number: 10/600,816

Art Unit: 1646

Information regarding the status of an application may be obtained from the Patent

Page 5

Application Information Retrieval (PAIR) system. Status information for published

applications may be obtained from either Private PAIR or Public PAIR. Status

information for unpublished applications is available through Private PAIR only. For

more information about the PAIR system, see http://pair-direct.uspto.gov. Should you

have questions on access to the Private PAIR system, please contact the Electronic

Business Center (EBC) at the toll-free phone number 866-217-9197.

Ruixiang Li

RUIXIANG LI, PH.D. PRIMARY EXAMINER

Ruixiang Li, Ph.D. Primary Examiner March 26, 2007